SYNEOS HEALTH INC (SYNH) Stock Price, Quote, News and Overview
NASDAQ:SYNH - Nasdaq - US87166B1026 - Common Stock - Currency: USD
SYNH Quote, Performance and Key Statistics
42.98
+0.01 (+0.02%)
The current stock price of SYNH is 42.98 USD. In the past month the price increased by 0.7%. In the past year, price decreased by -8.84%.
SYNH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
| DHR | DANAHER CORP | 28.07 | 151.18B | ||
| A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
| IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
| WAT | WATERS CORP | 31.58 | 22.26B | ||
| ICLR | ICON PLC | 14.39 | 16.63B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
| ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
| RVTY | REVVITY INC | 23.23 | 13.85B | ||
| AVTR | AVANTOR INC | 17.3 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 10.72B |
Related stock screener links
About SYNH
Company Profile
Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. The company is headquartered in Morrisville, North Carolina and currently employs 28,768 full-time employees. The company went IPO on 2014-11-07. The firm operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
Company Info
SYNEOS HEALTH INC
1030 Sync Street
Morrisville NORTH CAROLINA 27560 US
CEO: Alistair Macdonald
Employees: 28768
Company Website: https://www.syneoshealth.com/
Phone: 19198769300.0
SYNEOS HEALTH INC / SYNH FAQ
What is the stock price of SYNEOS HEALTH INC today?
The current stock price of SYNH is 42.98 USD. The price increased by 0.02% in the last trading session.
What is the ticker symbol for SYNEOS HEALTH INC stock?
The exchange symbol of SYNEOS HEALTH INC is SYNH and it is listed on the Nasdaq exchange.
On which exchange is SYNH stock listed?
SYNH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SYNEOS HEALTH INC stock?
16 analysts have analysed SYNH and the average price target is 43.35 USD. This implies a price increase of 0.86% is expected in the next year compared to the current price of 42.98. Check the SYNEOS HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SYNEOS HEALTH INC worth?
SYNEOS HEALTH INC (SYNH) has a market capitalization of 4.46B USD. This makes SYNH a Mid Cap stock.
How many employees does SYNEOS HEALTH INC have?
SYNEOS HEALTH INC (SYNH) currently has 28768 employees.
What are the support and resistance levels for SYNEOS HEALTH INC (SYNH) stock?
SYNEOS HEALTH INC (SYNH) has a support level at 42.81 and a resistance level at 42.99. Check the full technical report for a detailed analysis of SYNH support and resistance levels.
Is SYNEOS HEALTH INC (SYNH) expected to grow?
The Revenue of SYNEOS HEALTH INC (SYNH) is expected to decline by -2.82% in the next year. Check the estimates tab for more information on the SYNH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SYNEOS HEALTH INC (SYNH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SYNH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SYNH, evaluating the profitability, health, valuation and growth aspects
- SYNEOS HEALTH INC (SYNH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SYNEOS HEALTH INC (SYNH) Sales and EPS estimates to see what analysts future expectations are.
- SYNEOS HEALTH INC (SYNH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SYNEOS HEALTH INC (SYNH) Insider and Institutional Ownership to learn about the owners and their transactions.
- SYNEOS HEALTH INC (SYNH) Stock Chart to make your own analysis
- SYNEOS HEALTH INC (SYNH) Latest news and press-releases to stay up to date.
Does SYNEOS HEALTH INC (SYNH) stock pay dividends?
SYNH does not pay a dividend.
When does SYNEOS HEALTH INC (SYNH) report earnings?
SYNEOS HEALTH INC (SYNH) will report earnings on 2023-11-02, before the market open.
What is the Price/Earnings (PE) ratio of SYNEOS HEALTH INC (SYNH)?
The PE ratio for SYNEOS HEALTH INC (SYNH) is 11.37. This is based on the reported non-GAAP earnings per share of 3.78 and the current share price of 42.98 USD. Check the full fundamental report for a full analysis of the valuation metrics for SYNH.
SYNH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SYNH. When comparing the yearly performance of all stocks, SYNH turns out to be only a medium performer in the overall market: it outperformed 45.73% of all stocks.
SYNH Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SYNH. SYNH has only an average score on both its financial health and profitability.
SYNH Financial Highlights
Over the last trailing twelve months SYNH reported a non-GAAP Earnings per Share(EPS) of 3.78. The EPS decreased by -23.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.31% | ||
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| Debt/Equity | 0.77 |
SYNH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 54% to SYNH. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -25.43% and a revenue growth -2.82% for SYNH